2023年2月24日

根據未來市場觀察，2023年2月24日-2023年吸入給藥途徑預計將占據嚴重哮喘治療市場40%的市場份額:FMI研究在2023年至2033年預測期間，嚴重哮喘治療市場預計將以5.1%的複合年增長率增長。到2033年，全球嚴重哮喘治療市場預計將上升到361.8億美元的市場估值。市場的增長可以歸因於生物製劑和其他靶向療法的出現，因為它們徹底改變了嚴重哮喘的治療方法，為世界各地數百萬患有這種疾病的人帶來了希望和緩解。在治療嚴重哮喘方麵最有希望的發展之一是生物藥物的出現。生物製劑是一類由活生物體製成的藥物，可用於針對免疫係統中引起氣道炎症的特定途徑。這些藥物在臨床試驗中顯示出顯著療效，並越來越多地用於治療對傳統療法反應不佳的嚴重哮喘患者。一些最常用的用於嚴重哮喘治療的生物製劑包括omalizumab, mepolizumab, reslizumab, benralizumab和dupilumab。這些藥物通過皮下注射或靜脈輸注給藥，已被證明可以減少哮喘加重，改善肺功能，並提高嚴重哮喘患者的整體生活質量。總體而言，隨著越來越多的人被診斷出患有嚴重哮喘，以及新的創新治療方法的出現，全球嚴重哮喘治療市場預計將在未來幾年繼續增長。預計在2023-2033年預測期內，嚴重哮喘治療市場的複合年增長率為5.1%，預計2023年吸入給藥途徑將占據嚴重哮喘治療市場40%的市場份額。 North America is expected to possess 45% market share for severe asthma treatment market in 2023. Europe severe asthma treatment market size is expected to possess 39% market share in 2023. “Advancements in treatments along with innovation of treatment options is expected to favor the growth of the market in the upcoming years.” states an FMI analyst Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16760 Competitive Landscape Key players in the severe asthma treatment market are Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Regeneron Pharmaceutical, 4D Pharma plc, AB Pharma, Morphosys, Roche, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Pieris Pharma, Biosion GlaxoSmithKline most significant contributions to the treatment of severe asthma has been the development and commercialization of a biologic medication called Nucala (mepolizumab). Nucala is an anti-IL-5 monoclonal antibody that is used to treat severe eosinophilic asthma, a type of severe asthma that is characterized by high levels of eosinophils in the blood and airways. Novartis’ most significant contributions to the treatment of severe asthma has been the development and commercialization of a biologic medication called Xolair (omalizumab). Xolair is an anti-IgE monoclonal antibody that is used to treat severe allergic asthma, a type of severe asthma that is triggered by allergens such as pollen, dust mites, and animal dander. More Valuable Insights Future Market Insights, in its new offering, presents an unbiased analysis of the global severe asthma treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033. The study reveals essential insights on the basis of Drug Class (Reslizumab, Benralizumab, Anti-inflammatory) Route of Administration (Oral, Inhaled, Intravenous, Subcutaneous) Device Type (Dry powder inhalers, Metered dose inhalers, Soft mist inhalers) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, MEA)